ASH

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied.

Read More ›

The current study found no clear evidence linking eltrombopag treatment and risk for cataract development/progression in patients with chronic immune thrombocytopenia (ITP). Read More ›

The current post-hoc subanalysis of a phase 4 open-label study concluded that the effects on platelet counts after eltrombopag treatment for >2 years was comparable between the persistent immune thrombocytopenia (ITP) and the chronic ITP cohorts, with similar safety profiles. Read More ›

These study results showed that heavily pretreated patients with persistent/chronic immune thrombocytopenia (ITP) who achieved a stable response with fostamatinib therapy maintained their responses for ≥12 months. Read More ›

Results of this randomized, placebo-controlled phase 3 trial showed that avatrombopag was superior to placebo in terms of the cumulative number of weeks with a platelet response, platelet response at day 8, and durability of platelet response in patients with refractory chronic immune thrombocytopenia (ITP). Read More ›

This open-label study reported that the majority of children with immune thrombocytopenia (ITP) who received open-label romiplostim for ≥6 months achieved a platelet response, with median platelet counts >50 × 109/L from week 12 onward and no new safety signals observed during the study period. Read More ›

Educating Your Patients About Daratumumab
Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time. Read More ›

How to Handle Survivorship Care for Multiple Myeloma
Tiffany Richards insists on the importance of survivorship care in patients with multiple myeloma and explains how to make sure patients stay as healthy as possible for as long as possible. Read More ›

How to Utilize New Mutliple Myeloma Drugs
Tiffany Richards is excited about all the new multiple myeloma treatments that are being introduced, but understands that the question of how to best utilize these drugs still remains to be answered. Read More ›

Preparing Your Patients for Side Effects
Tiffany Richards stresses the importance of educating patients about side effects and what to do when these side effects begin to present. Read More ›

Page 2 of 12


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: